It seems NSCLC is proving a somewhat thornier beast than the majors had perhaps anticipated.
If OS is the main game and Merck does want to roll Pembro/CVA-21 combo into something more substantial in NSCLC because of their superior OS experiences, I would like to think VLA will squeeze their goolies so they cough up for the right to play together.
Show me the money.
Keytruda and Merck article about problems with lung cancer trial., page-5
Add to My Watchlist
What is My Watchlist?